Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Inventory (2018 - 2025)

Historic Inventory for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Q3 2025 value amounting to $28.0 million.

  • Catalyst Pharmaceuticals' Inventory rose 4002.6% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 4002.6%. This contributed to the annual value of $19.5 million for FY2024, which is 2491.05% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Inventory is $28.0 million, which was up 4002.6% from $18.6 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Inventory high stood at $28.0 million for Q3 2025, and its period low was $4.4 million during Q1 2021.
  • Its 5-year average for Inventory is $12.9 million, with a median of $10.3 million in 2023.
  • In the last 5 years, Catalyst Pharmaceuticals' Inventory skyrocketed by 28825.47% in 2021 and then plummeted by 1353.24% in 2022.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Inventory stood at $7.9 million in 2021, then decreased by 13.53% to $6.8 million in 2022, then soared by 129.89% to $15.6 million in 2023, then increased by 24.91% to $19.5 million in 2024, then surged by 43.44% to $28.0 million in 2025.
  • Its last three reported values are $28.0 million in Q3 2025, $18.6 million for Q2 2025, and $19.8 million during Q1 2025.